Equillium (FRA:0FY) Debt-to-Equity

: 0.04 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Equillium's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.40 Mil. Equillium's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.35 Mil. Equillium's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €20.70 Mil. Equillium's debt to equity for the quarter that ended in Dec. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Equillium's Debt-to-Equity or its related term are showing as below:

FRA:0FY' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.58 Med: 0.16 Max: 0.32
Current: 0.04

During the past 7 years, the highest Debt-to-Equity Ratio of Equillium was 0.32. The lowest was -3.58. And the median was 0.16.

FRA:0FY's Debt-to-Equity is ranked better than
76.49% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs FRA:0FY: 0.04

Equillium Debt-to-Equity Historical Data

The historical data trend for Equillium's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.23

0.14

0.18

0.32

0.04

Equillium Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.32	0.30	0.04	0.04	0.04

Competitive Comparison

For the Biotechnology subindustry, Equillium's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Equillium Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Equillium's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Equillium's Debt-to-Equity falls into.

Equillium Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Equillium's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.403	+	0.352)	/	20.699
	=	0.04

Equillium's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.403	+	0.352)	/	20.699
	=	0.04

Equillium (FRA:0FY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Equillium Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Equillium's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (FRA:0FY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (FRA:0FY) Headlines

No Headlines